AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial

A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage trial as a potential fix for overactive bladder and urinary incontinence.